Company profile for Iterum Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Headquartered in Dublin, Ireland, we are a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. We are pursuing a balanced development strategy with multiple opportunities intended to t...
Headquartered in Dublin, Ireland, we are a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. We are pursuing a balanced development strategy with multiple opportunities intended to treat the organisms responsible for many serious infections, which the Centers for Disease Control (CDC) has determined to be inadequately addressed by current therapies

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
200 S Wacker Drive Suite 2550 Chicago, IL 60606
Telephone
Telephone
+1 312 778 6070
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercepharma.com/pharma/breaking-down-dual-track-strategy-behind-iterums-launch-first-new-uncomplicated-uti-drug

FIERCE PHARMA
20 Aug 2025

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-iterums-treatment-urinary-infection-2024-10-25/

REUTERS
26 Oct 2024

https://www.fiercebiotech.com/biotech/fda-concerned-iterums-urinary-tract-infection-drug-could-cause-antimicrobial-resistance

FIERCE BIOTECH
06 Sep 2024

https://www.prnewswire.com/news-releases/iterum-therapeutics-announces-positive-topline-results-from-its-phase-3-reassure-clinical-trial-of-oral-sulopenem-in-uncomplicated-urinary-tract-infections-302047483.html

PR NEWSWIRE
30 Jan 2024

https://www.globenewswire.com/news-release/2023/01/11/2587531/0/en/Iterum-Therapeutics-Reports-Employment-Inducement-Grant.html

GLOBENEWSWIRE
11 Jan 2023

https://www.globenewswire.com/news-release/2022/12/15/2574503/0/en/Iterum-Therapeutics-announces-Issuance-of-Allowance-for-a-U-S-Patent-Covering-Oral-Sulopenem.html

GLOBENEWSWIRE
15 Dec 2022

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty